Exelixis Inc. (EXEL)
Exelixis: RCC Stronghold, NET Launch, And A CRC Readout That Matters
CABOMETYX remains the leading TKI in renal cell carcinoma, driving strong revenue growth and expanding into new indications like neuroendocrine tumors. Exelixis's pipeline, led by zanzalintinib, shows promising Phase 3 results in colorectal cancer, offering a credible path to future revenue diversification. Financially robust with $1.4B in cash, active share buybacks, and stable commercial trends, Exelixis is well-positioned despite looming CABOMETYX exclusivity loss.
Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?
EXEL rides on Cabometyx momentum and pipeline gains, while MRK leans on Keytruda dominance and a diverse portfolio for growth.
Will EXEL's Share Repurchase Program Boost Value for Investors?
Exelixis repurchases shares for $796M, aiming to boost EPS and shareholder value through 2025.
Exelixis Gains 15.6% YTD: How Should You Play the Stock?
EXEL rides on Cabometyx growth and zanzalintinib's trial success, but Q2 revenue miss and competition keep investor sentiment cautious.
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?
Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.
Don't Overlook Exelixis (EXEL) International Revenue Trends While Assessing the Stock
Explore how Exelixis' (EXEL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
EXEL beats on Q2 earnings but misses revenues as lower collaboration income offsets strong Cabometyx sales growth.
Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Q2 2025 Earnings Conference Call July 28, 2025 5:00 PM ET Company Participants l - Corporate Participant Amy C. Peterson - Executive VP of Product Development & Medical Affairs and Chief Medical Officer Christopher J.
Exelixis (EXEL) Beats Q2 Earnings Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.84 per share a year ago.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
